PharmaShots | Incisive News in 3 Shots

Subscribe Now

Coherus

Coherus Launches Yusimry (biosimilar, adalimumab) in the US at 85% Discount

Coherus Launches Yusimry (biosimilar, adalimumab) in the US at 85% Discount

July 3, 2023

Coherus Receives the US FDA’s Approval of Udenyca (biosimilar, pegfilgrastim) for Febrile Neutropenia

Coherus Receives the US FDA’s Approval of Udenyca (biosimilar, pegfilgrastim) for Febrile Neutropenia

March 7, 2023

Coherus and Junshi Biosciences Report P-III Trial (JUPITER-02) Results of Toripalimab for Recurrent or Metastatic Nasopharyngeal Carcinoma

Coherus and Junshi Biosciences Report P-III Trial (JUPITER-02) Results of Toripalimab for Recurrent or Metastatic Nasopharyngeal C...

February 16, 2023

Coherus Acquires Rights from Klinge Biopharma for Eylea Biosimilar Candidate

Coherus Acquires Rights from Klinge Biopharma for Eylea Biosimilar Candidate

January 9, 2023

Coherus’ Cimerli (biosimilar, ranibizumab) Receives the US FDA’s Approval as a First Interchangeable Biosimilar for the Treatment of Retinal Disease

Coherus’ Cimerli (biosimilar, ranibizumab) Receives the US FDA’s Approval as a First Interchangeable Biosimilar for the Treatment...

August 3, 2022

Insights+ Key Biosimilars Events of May 2022

Insights+ Key Biosimilars Events of May 2022

June 2, 2022

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us